COVID-19 convalescent plasma transfusion

Langhi, Dante Mário; Santis, Gil Cunha De; Bordin, José Orlando

doi:10.1016/j.htct.2020.04.003

Cited by 34 publications

(30 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The variable dosing of CP, 28,44 its co-administration with antiviral or other therapies can also affect the relationship between CP and antibody leading to result discrepancies. 36,44 Studies have reported a differential response of viruses based on the stage. While infections like SARS peak in the first week of infection, patients usually develop an immune response which probably causes a lethal cytokine storm in the second week.…”

Section: Challenges Of Cp Therapy In Covid-19mentioning

confidence: 99%

“…Hence, optimal timing of CP transfusion in COVID-19 needs to be carefully considered. 43,44 Finally, it must be determined whether plasma from donors with no clinical symptoms offers more protection than those with clinical symptoms. 44 An RCT is the finest model to determine the efficacy, tolerability, and safety of a therapy.…”

Section: Challenges Of Cp Therapy In Covid-19mentioning

confidence: 99%

“…43,44 Finally, it must be determined whether plasma from donors with no clinical symptoms offers more protection than those with clinical symptoms. 44 An RCT is the finest model to determine the efficacy, tolerability, and safety of a therapy. 45 Patients are being recruited to the CONCOVID trial in The Netherlands by the Erasmus Medical Center to test the CP from patients recovered from COVID-19 as therapy for hospitalized patients with COVID-19 with an estimated enrollment of more than 400 patients.…”

Section: Challenges Of Cp Therapy In Covid-19mentioning

confidence: 99%

See 2 more Smart Citations

Convalescent plasma appears efficacious and safe in COVID-19

Khulood

Adil

Sultana

et al. 2020

Therapeutic Advances in Infection

View full text Add to dashboard Cite

A cluster of pneumonia cases of unknown etiology associated with pyrexia and acute respiratory distress was identified in Southern China. Links between the previous severe acute respiratory syndrome (SARS) cases and the region’s seafood market were noted with the possibility of a new zoonosis and SARS-CoV-2 was identified as the responsible agent. Currently, there are no effective prophylactic or therapeutic options to deal with coronavirus disease-19 (COVID-19) or any other human coronavirus (HCoV) infections. Convalescent plasma (CP) therapy is a classic adaptive immunotherapy which has been in use for more a century to prevent and treat infections including SARS, Middle East respiratory syndrome (MERS), and H1N1 pandemic. Moreover, the World Health Organization regarded CP transfusion as the most promising therapy to treat MERS-CoV. This review was undertaken to demonstrate the potential of CP in the treatment of the pandemic COVID-19 disease. A total of eight studies conducted on CP therapy in patients with COVID-19 were reviewed wherein 25,028 patients above 18 years of age were involved. The vast majority of patients reported favorable outcomes when treated with CP with <1% serious adverse events. Despite its promising beneficial effects in patients severely ill with COVID-19, CP therapy requires further evaluation in randomized clinical trials (RCTs) as a lack of satisfactory efficacy data from this area certainly enhances the hesitancy with regard to employing this treatment. In the present circumstances of unsatisfactory pharmacological therapy and the urgent need for a successful curative remedy, considering the use of CP therapy is reasonable provided RCTs confirm its safety, efficacy, and tolerability.

show abstract

Section: Challenges Of Cp Therapy In Covid-19mentioning

confidence: 99%

Section: Challenges Of Cp Therapy In Covid-19mentioning

confidence: 99%

Section: Challenges Of Cp Therapy In Covid-19mentioning

confidence: 99%

See 1 more Smart Citation

Convalescent plasma appears efficacious and safe in COVID-19

Khulood

Adil

Sultana

et al. 2020

Therapeutic Advances in Infection

View full text Add to dashboard Cite

show abstract

“…[4] Most of the COVID-19 patients are either asymptomatic or presents with mild symptoms, and in some patients it progresses to severe acute respiratory syndrome (SARS) which is the main cause of mortality. [5] Until now, no specific antiviral drugs and vaccine have been found to cure and prevent the infection. Therefore, it is necessary to discuss scientifically and ethically all the therapeutic options for the lethal COVID-19 infections.…”

Section: Introductionmentioning

confidence: 99%

“…Therefore, it is necessary to discuss scientifically and ethically all the therapeutic options for the lethal COVID-19 infections. [5] Several treatment options such as favipiravir and remdesivir are under investigation, but their antiviral efficacy is not yet known. [6] In the past, the Passive Immunotherapy (PIT) has been used as a possible treatment option when no proven drugs or specific vaccine was available for the emerging infections.…”

Section: Introductionmentioning

confidence: 99%

Convalescent Plasma Therapy in Coronavirus Disease 2019 (COVID-19) Patients: A Brief Review

Khan¹

2020

JRI

View full text Add to dashboard Cite

The recent outbreak of the COVID-19 pandemic has reevaluated effectiveness of the convalescent plasma therapy (CPT). This review was carried out to assess the usefulness of CPT in critically COVID-19 patients, based on the published data to date. To the best of our knowledge, this is the second review of the usefulness of CPT in COVID-19 patients. PubMed, Google Scholar, Medline and EMBASE databases were searched for the relevant reports up to June 21, 2020. All the records of the published data were analyzed according to eligibility criteria protocols. Five different studies on CPT for COVID-19 critically ill patients were included in this review. The significant findings from the records are: (a) the CPT may help to reduce mortality in the seriously ill patients (b) administration of CPT increased antibodies titer and reduced the level of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) RNA beyond detection limit (c) transfusion of convalescent plasma (CP) subsided clinical symptoms. Based on the currently available data, the CPT in the COVID-19 patients seems effective, safe and reduces mortality. There is urgent need of performing well-designed, multicenter clinical trials for establishing efficacy of the CPT in COVID-19 patients.

show abstract